Accredited Investors Inc. Verve Therapeutics, Inc. Transaction History
Accredited Investors Inc.
- $1.68 Billion
- Q3 2024
A detailed history of Accredited Investors Inc. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Accredited Investors Inc. holds 20,000 shares of VERV stock, worth $114,800. This represents 0.01% of its overall portfolio holdings.
Number of Shares
20,000
Previous 6,397
212.65%
Holding current value
$114,800
Previous $30,000
220.0%
% of portfolio
0.01%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding VERV
# of Institutions
186Shares Held
73.3MCall Options Held
85KPut Options Held
215K-
Alphabet Inc. Mountain View, CA12.3MShares$70.9 Million4.09% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$38 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.96MShares$28.5 Million0.01% of portfolio
-
State Street Corp Boston, MA4.25MShares$24.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$23 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $344M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...